Natural killer cell-based strategies for immunotherapy of cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F22%3A10448230" target="_blank" >RIV/00216208:11310/22:10448230 - isvavai.cz</a>
Result on the web
<a href="https://doi.org/10.1016/bs.apcsb.2022.02.001" target="_blank" >https://doi.org/10.1016/bs.apcsb.2022.02.001</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/bs.apcsb.2022.02.001" target="_blank" >10.1016/bs.apcsb.2022.02.001</a>
Alternative languages
Result language
angličtina
Original language name
Natural killer cell-based strategies for immunotherapy of cancer
Original language description
Natural killer (NK) cells are a family of lymphocytes with a natural ability to kill infected, harmed, or malignantly transformed cells. As these cells are part of the innate immunity, the cytotoxic mechanisms are activated upon recognizing specific patterns without prior antigen sensitization. This recognition is crucial for NK cell function in the maintenance of homeostasis and immunosurveillance. NK cells not only act directly toward malignant cells but also participate in the complex immune response by producing cytokines or cross-talk with other immune cells. Cancer may be seen as a break of all immune defenses when malignant cells escape the immunity and invade surrounding tissues creating a microenvironment supporting tumor progression. This process may be reverted by intervening immune response with immunotherapy, which may restore immune recognition. NK cells are important effector cells for immunotherapy. They may be used for adoptive cell transfer, genetically modified with chimeric antigen receptors, or triggered with appropriate antibodies and other antibody-fragment-based recombinant therapeutic proteins tailored specifically for NK cell engagement. NK cell receptors, responsible for target recognition and activation of cytotoxic response, could also be targeted in immunotherapy, for example, by various bi-, tri-, or multi-specific fusion proteins designed to bridge the gap between tumor markers present on target cells and activation receptors expressed on NK cells. However, this kind of immunoactive therapeutics may be developed only with a deep functional and structural knowledge of NK cell receptor: ligand interactions. This review describes the recent developments in the fascinating protein-engineering field of NK cell immunotherapeutics.
Czech name
—
Czech description
—
Classification
Type
C - Chapter in a specialist book
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
—
Continuities
S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Book/collection name
Immunotherapeutics
ISBN
978-0-323-99227-5
Number of pages of the result
43
Pages from-to
91-133
Number of pages of the book
477
Publisher name
Elsevier Science & Technology, Academic Press Inc.
Place of publication
San Diego
UT code for WoS chapter
—